Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer

Lynparza Approved in U.S. as First-line Maintenance Therapy for BRCA-positive Advanced Ovarian Cancer
Women with BRCA-mutated advanced ovarian cancer living in the United States can now receive Lynparza (olaparib), developed by AstraZeneca and Merck, as a maintenance treatment for their partial or complete response to first-line platinum-based chemotherapy. The U.S. Food and Drug Administration’s decision makes Lynparza the first PARP inhibitor to be approved as a first-line maintenance therapy for BRCA-mutated

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *